<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521963</url>
  </required_header>
  <id_info>
    <org_study_id>0088-07-EMC</org_study_id>
    <nct_id>NCT00521963</nct_id>
  </id_info>
  <brief_title>Intraarticular Injection of Infliximab</brief_title>
  <official_title>Interventional Study: Administration of Intraarticular Injection of Infliximab in Patients With Inflammatory Arthritis Who Failed Intraarticular Injection of Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intra-articular (IA) injection of medication is a common procedure in the management of joint&#xD;
      disorders. In particular, the procedure is effective in the treatment of inflammatory&#xD;
      conditions, with long acting corticosteroids most commonly used. These agents have been shown&#xD;
      to reduce the signs and symptoms of inflammation, expressed primarily in the synovium of the&#xD;
      joint, and are probably capable of slowing the progression of damage to joint cartilage and&#xD;
      bone in some of these inflammatory conditions. Arthritis that is refractory to IA&#xD;
      corticosteroid injections may respond to surgical, chemical, or, radioisotope synovectomy,&#xD;
      procedures in which the inflamed synovial tissue is eradicated. It has been noted that&#xD;
      infliximab, a monoclonal antibody directed to Tumor Necrosis Factor (TNF) - α, has high&#xD;
      affinity for the TNF-α rich inflamed synovium. Recently, clinical benefit from IA injections&#xD;
      of infliximab has been reported in some cases that were refractory to IA injections of&#xD;
      corticosteroids. Similarly, the effectiveness of IA infliximab in suppression of joint&#xD;
      inflammation has also been demonstrated in patients who could not receive systemic therapy&#xD;
      with infliximab. These reports examined the effect of a single injection of infliximab100 mg&#xD;
      injected into a large inflamed joint or 2 IA injections 24 hours apart.&#xD;
&#xD;
      We propose to further evaluate the use of IA infliximab in patients with intractable knee&#xD;
      monoarthritis, explore the optimal mode of its employment, and assess the degree of&#xD;
      infliximab systemic absorption from the IA injection. In a pilot study 40 knees will be&#xD;
      evaluated, 20 injected with infliximab and 20 injected with a corticosteroid comparator&#xD;
      reflecting the current standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>suppression of inflammation</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of systemic absorbtion</measure>
    <time_frame>2,4,8,12weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intraarticular injection of infliximab</intervention_name>
    <description>A single injection of 100 mg of infliximab</description>
    <arm_group_label>E</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have non-infectious monoarthritis of the knee and with inadequate response to IA&#xD;
             injection of corticosteroids, at least 3 months before enrollment.&#xD;
&#xD;
        or&#xD;
&#xD;
          -  Have oligo or polyarthritis controlled by disease modifying agents (DMARDs) but with&#xD;
             residual 1-2 inflamed joints, one of which is a knee with inadequate response to IA&#xD;
             injection of corticosteroids within 3 months&#xD;
&#xD;
          -  Have negative PPD skin test.&#xD;
&#xD;
          -  Have no evidence of TB on chest x-ray.&#xD;
&#xD;
          -  Be negative for HBsAg and HCV.&#xD;
&#xD;
          -  No evidence of infectious arthritis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to infliximab.&#xD;
&#xD;
          -  Known allergy to lidocaine.&#xD;
&#xD;
          -  Pregnant.&#xD;
&#xD;
          -  Female patients with childbearing potential who do not practice effective methods of&#xD;
             contraception.&#xD;
&#xD;
          -  Suffer from a chronic infection.&#xD;
&#xD;
          -  On systemic anti TNF-α or other biologic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuven Mader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ha'Emek Medical Center, Afula, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center and Lin outpatient service</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Schatteman L, Gyselbrecht L, De Clercq L, Mielants H. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. J Rheumatol. 2006 Jan;33(1):82-5. Epub 2005 Nov 15.</citation>
    <PMID>16292792</PMID>
  </reference>
  <reference>
    <citation>Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valesini G, Signore A. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum. 2005 Apr;52(4):1224-6.</citation>
    <PMID>15818709</PMID>
  </reference>
  <reference>
    <citation>Nikas SN, Temekonidis TI, Zikou AK, Argyropoulou MI, Efremidis S, Drosos AA. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis. 2004 Jan;63(1):102-3.</citation>
    <PMID>14672902</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <keyword>Intraarticular injection</keyword>
  <keyword>Infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

